Rethinking Clinical Trials

OCTOBER 26, 2023

Untreated, chronic Hepatitis C infection leads to liver damage, liver cancer, and death. Tags #pctGR, @Collaboratory1 The post Grand Rounds October 20, 2023: A National Initiative to Eliminate Hepatitis C in the United States – Why This Matters to Clinical Trialists (Rachael L. Rates are the highest among 20-39-year-olds.

Clinical Research 141

Clinical Research Clinical Trials Clinical Trials Research 141

Delveinsight

FEBRUARY 25, 2021

The GuideTx technology screens for lipid nanoparticles inside the body that can be used to deliver RNA to cells throughout the body. GRAIL and Quest collaborate for the cancer blood test. The study hints that this reduction could translate to a 39% reduction in five-year cancer deaths for patients who had their cancer detected earlier.

DNA 52

DNA In-Vivo Genetics Medicine 52

Drug Discovery World

APRIL 17, 2023

Totus Medicines has dosed its first patient in a Phase I clinical trial of TOS-358, a first-in-class covalent PI3Kα inhibitor for the treatment of numerous cancers with known PIK3CA mutations. The study will be conducted in two parts.

Clinical Trials 52

Clinical Trials Clinical Trials Trials Medicine 52

Roots Analysis

SEPTEMBER 13, 2023

These molecules can be conjugated with various modalities, such as haptens, enzymes, isotopes, fluorescent tags, carrier proteins, polymers, particle conjugates and photoreactive molecules. Further, small molecules are conjugated with carrier protein to confirm the production of antibody via ELISA screening.

Development 40

Development Antibody Protein Drug Delivery Systems 40

pharmaphorum

OCTOBER 4, 2022

In this article, Ben Hargreaves takes a look at the renewed effort to tackle deaths from cancer in the US through the Cancer Moonshot. Central to the initiative is the aim to gather data from willing participants that can provide greater insights into cancer development and treatment over time. Building a bank.

Biobanking 104

Biobanking Clinical Trials Clinical Trials Trials 104

Drug Discovery World

NOVEMBER 13, 2023

Novel/alternative ML-enabled screening technologies for higher POS Following chairperson’s remarks from M Frank Erasmus, PhD, Head, Bioinformatics, Specifica, there will be four presentations and a panel discussion. Jeremy Fry, Dr, Director of Sales, ProImmune, on: ‘Mastering immunogenicity and biologics development’.

Protein 59

Protein Antibody Engineer Scientist 59

Drug Discovery World

NOVEMBER 9, 2023

Novel platforms This session will begin with chariperson’s remarks from Lars Linden, PhD, Vice President, Head, Biologics Research, Bayer HealthCare, which will be followed by a keynote presentation by Agnieszka Kielczewska, PhD, Director, Research, Antibody Discovery and Screening, Biologics Discovery, Amgen.

Engineer 52

Engineer Antibody Protein In-Vivo 52